The latest price target for AVITA Medical (NASDAQ:RCEL) was reported by D. Boral Capital on February 20, 2025. The analyst firm set a price target for $22.00 expecting RCEL to rise to within 12 months (a possible 125.64% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for AVITA Medical (NASDAQ:RCEL) was provided by D. Boral Capital, and AVITA Medical maintained their buy rating.

There is no last upgrade for AVITA Medical

The last downgrade for AVITA Medical Inc happened on May 14, 2024 when Piper Sandler changed their price target from $21 to $9 for AVITA Medical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AVITA Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AVITA Medical was filed on February 20, 2025 so you should expect the next rating to be made available sometime around February 20, 2026.

While ratings are subjective and will change, the latest AVITA Medical (RCEL) rating was a maintained with a price target of $25.00 to $22.00. The current price AVITA Medical (RCEL) is trading at is $9.75, which is out of the analyst’s predicted range.